'Everybody says it about their strategy but this is why ours is different'

Does anyone else have the impression that PBS decision-making is suffering from a dangerous lack of political and policy interest?

Contributions can still be made to the 2023 'Kosi Challenge' but MSD has taken this year's 'Pharma Cup' while an industry executive has also raised the single largest amount by an individual.

Sister2sister vice chair Alecia Wood and welfare manager Linda Beuzeville visited Organon on International Women's Day and spoke about the importance of supporting girls as they develop their sense of place in society.

With this program, we can help Australia’s world-class medical research and biotech community to be at the forefront of contributions to unlocking the potential of mRNA science," said Moderna general manager Michael Azrak.

Dr Xiaobin Wu is BeiGene’s president, its chief operating officer and the general manager of the company in China. Dr Wu spoke with BioPharmaDispatch during his current visit to Australia. 

A change in the membership of the federal government's HTA review reference committee. What does it say about the review and what does it mean? Still waiting for final outcomes ahead of the 1 April price changes and a question from the audience about what patients can do to ensure their voices are heard.

Taken at face value, it means that the minister's own officials did not communicate the company's intention to remove these medicines from the PBS as a result of the catch-up reduction.

The Perth-based company said the response of Australian payers to the home-grown innovation stands in stark contrast to the "traction" gained in the US and UK.

The pharmaceutical company teams supporting Rare Cancers Australia and this week's 'Kosi Challenge' added almost $50,000 to the fundraising total yesterday with the annual event just one day away.

A leading patient organisation says the decision to reduce access to paracetamol will significantly hit people on low incomes and those living in rural and regional areas

A ground-breaking Australian and world-first study examining a new non-surgical treatment for Type 2 diabetes is now being expanded to include people in advanced stages of the disease.

What has John Young observed that led him to choose his new corporate responsibilities over the review? What does this say about the review in which so much hope is invested?

The post-pandemic Budget reality does not make a renewed policy assault on the PBS inevitable but it certainly increases the likelihood.

Just two weeks to go until the single largest day of medicine price reductions in the history of the PBS and there is still no real insight into what the industry is 'on the hook' to deliver.

The medicines supply chain is experiencing the practical challenges of 1 April's catch-up statutory price reduction and is yet to even receive confirmation of the final outcomes.

Sanofi has opened the first tranche of senior medical research career opportunities available at its Translational Science Hub in Queensland.

“Pfizer is deploying its financial resources to advance the battle against cancer, a leading cause of death worldwide with a significant impact on public health,” said Dr Albert Bourla, Pfizer chairman and CEO.

New Zealand's controversial medicines purchasing agency Pharmac has announced that it will fund MSD's KEYTRUDA (pembrolizumab) and Roche's TECENTRIQ (atezolizumab) for people with locally advanced and metastatic non-small cell lung cancer.

The market capitalisation of Australian company Neuren Pharmaceuticals has surged 20 per cent to almost $1 billion after it announced that the US FDA has approved its treatment for Rett syndrome.